Cargando…

Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial

IMPORTANCE: Mavacamten, a cardiac myosin inhibitor, improved peak oxygen uptake (pVO(2)) in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the EXPLORER-HCM study. However, the full extent of mavacamten’s effects on exercise performance remains unclear. OBJECTIVE: To inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wheeler, Matthew T., Olivotto, Iacopo, Elliott, Perry M., Saberi, Sara, Owens, Anjali T., Maurer, Mathew S., Masri, Ahmad, Sehnert, Amy J., Edelberg, Jay M., Chen, Yu-Mao, Florea, Victoria, Malhotra, Rajeev, Wang, Andrew, Oręziak, Artur, Myers, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857843/ https://www.ncbi.nlm.nih.gov/pubmed/36652223 http://dx.doi.org/10.1001/jamacardio.2022.5099

Ejemplares similares

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
por: Edelberg, Jay M., et al.
Publicado: (2022)

Mavacamten: First Approval
por: Keam, Susan J.
Publicado: (2022)

Sudden Cardiac Death Risk over Time in HCM Patients with Implantable Cardioverter-Defibrillator
por: Klopotowski, Mariusz, et al.
Publicado: (2022)

Correction to: Mavacamten: First Approval
por: Keam, Susan J.
Publicado: (2022)

Foreword to the Special Issue: HCM in 2018
por: Elliott, Perry
Publicado: (2018)

Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program
por: Kassem, Heba Sh., et al.
Publicado: (2012)

Histopathology in HCM
por: Tejado, Beatriz San Millán, et al.
Publicado: (2018)

Erratum to: Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program
por: Kassem, Heba Sh., et al.
Publicado: (2013)

External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy
por: Norrish, Gabrielle, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
por: Dong, Tiffany, et al.
Publicado: (2023)

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
por: Scholtz, Smita, et al.
Publicado: (2023)

Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial
por: Reaney, Matthew, et al.
Publicado: (2022)

Follow-up and prognosis of HCM
por: Dominguez, Fernando, et al.
Publicado: (2018)

Vigorous Exercise in Patients with Hypertrophic Cardiomyopathy: Results of the Prospective, Observational, Multinational, “Lifestyle and Exercise in HCM” (LIVE-HCM) Study
por: Lampert, Rachel, et al.
Publicado: (2023)

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten
por: Mathai, Susan, et al.
Publicado: (2022)

Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM
por: Pioner, Josè Manuel, et al.
Publicado: (2023)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
por: Masri, Ahmad, et al.
Publicado: (2022)

International HCM Workshop: Innovative Time Integrators
Publicado: (1996)

Perspectives on current recommendations for genetic testing in HCM
por: Monserrat, Lorenzo
Publicado: (2018)

Regional adenosine-induced hypoperfusion without hyperenhancement on LGE-MRI in young HCM patients: comparison to subjects at risk of HCM and healthy volunteers
por: Jablonowski, Robert, et al.
Publicado: (2015)

Myosin in autoinhibited off state(s), stabilized by mavacamten, can be recruited via inotropic effectors
por: Ma, Weikang, et al.
Publicado: (2023)

Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis
por: Memon, Areeba, et al.
Publicado: (2023)

Ischaemia as a cause of LVOT gradient reversal in HCM
por: Demetrescu, Camelia, et al.
Publicado: (2017)

Septal Ablation in Obstructive Hypertrophic Cardiomyopathy (oHCM)
por: Almeida, Dirceu Rodrigues
Publicado: (2019)

Mitochondrial Localization of the Yeast Forkhead Factor Hcm1
por: Rodríguez Colman, María José, et al.
Publicado: (2020)

The Feline Cardiomyopathies: 3. Cardiomyopathies other than HCM
por: Kittleson, Mark D, et al.
Publicado: (2021)

Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk‐CVA)
por: Guttmann, Oliver P., et al.
Publicado: (2015)

The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients
por: DeVries, J Hans, et al.
Publicado: (2023)

Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy
por: Taddei-Allen, Patty
Publicado: (2022)

MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM
por: Li, Mengmeng, et al.
Publicado: (2018)

Association between Lifelong Physical Activity and Disease Characteristics in HCM
por: AENGEVAEREN, VINCENT L., et al.
Publicado: (2019)

New evidences recommend an active lifestyle in young HCM patients
por: Pelliccia, Antonio
Publicado: (2022)

Molecular Diagnosis of Hypertrophic Cardiomyopathy (HCM): In the Heart of Cardiac Disease
por: Melas, Marilena, et al.
Publicado: (2022)

Global extracellular volume (ECVglobal) in HCM - the "next generation" test for risk in hypertrophic cardiomyopathy?
por: Sado, Daniel, et al.
Publicado: (2013)

Patients with hypertrophic cardiomyopathy (HCM) and HCM gene carriers have attenuated myocardial oxygenation response to vasodilator stress - a potential mechanism for sudden cardiac death
por: Dass, Sairia, et al.
Publicado: (2012)

Impact of the Myosin Modulator Mavacamten on Force Generation and Cross‐Bridge Behavior in a Murine Model of Hypercontractility
por: Mamidi, Ranganath, et al.
Publicado: (2018)

Single-molecule imaging reveals how mavacamten and PKA modulate ATP turnover in skeletal muscle myofibrils
por: Pilagov, Matvey, et al.
Publicado: (2022)

Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial
por: Tian, Zhuang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4hfnbdnlg8v106kei7fhgu3f9e